Chemical Structure (Levetiracetam 01)
Levetiracetam Injection, Solution
Product Images NDC 0409-1886
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 0409-1886). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Levetiracetam 02)
This document appears to be a statistical summary of the results of clinical trials comparing the effects of placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day on patient outcomes. The percentages shown relate to different aspects of the patient sample, but further details can be gleaned from the original source.*
Figure 2 (Levetiracetam 03)
This text provides information regarding the comparison of a placebo group (N=111) with two different doses of Levetiracetam, 1000 mg/day (N=106) and 2000 mg/day (N=105). The study appears to be evaluating the effects of these dosages on a certain condition or outcome.*
Figure 3 (Levetiracetam 04)
Figure 4 (Levetiracetam 05)
Not available.*
Figure 5 (Levetiracetam 06)
Levetiracetam is a medication with a dosage of 5% 43.1% 19.6%.*
Figure 6 (Levetiracetam 07)
This appears to be a summary of percentages, likely related to some data comparison or evaluation. The text mentions 100%, 0%, s0%, 0%, along with numbers like 45.2% and 72.2%, and the label "Placebo (N=84)" which might indicate a comparison group or condition. The context of these percentages is not entirely clear, suggesting that further details would be needed to fully understand the information provided.*
Logo (Levetiracetam 08)
Principal Display Panel (5 mL Vial Label)
This is a description of a single-dose vial containing 5mL of Levetiraceta Injection USP with a concentration of 500 mg/5 mL (100 mg/mL). It is intended for intravenous use only and must be diluted before administration. The recommended storage temperature is between 20 to 25°C. The manufacturer is Gland Pharma Limited in India, and the product is manufactured for Hospira, Inc. in Lake Forest, Illinois, USA. Unused portions should be discarded. For detailed description and dosage information, refer to the package insert.*
Principal Display Panel (5 mL Vial Carton)
This is a description of a medication called Levetiracetam injection in single-dose vials containing 500 mg/5 mL (100 mg/mL). The medication is designated for intravenous use only and must be diluted before administration. Each vial has a discard instruction for any unused portion. The storage temperature recommendation is between 20 to 25°C. The manufacturer is Gland Pharma Limited located in Hyderabad, India, and it is manufactured for Hospira in Lake Forest, USA. The National Drug Code (NDC) for this product is NDC0409-1886-02.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
